FDA In Brief: FDA requires new warnings for gabapentinoids about risk of respiratory depression

Over-the-Counter Monograph Drug User Fee annual performance reports to Congress

Antifungal Susceptibility Test Interpretive Criteria

FDA Update on the Safety of Ixchiq (Chikungunya Vaccine, Live). FDA Removes Recommended Pause in Use and Approves Required Updated Labeling: FDA Safety Communication

The U.S. Food and Drug Administration today initiated the process for a label change for acetaminophen (Tylenol and similar products) to reflect evidence suggesting that the use of acetaminophen by pregnant women may be associated with an increased risk of neurological conditions such as autism and

Unapproved New Drug/Misbranded

Consumers should not to purchase or use Force Forever, a product promoted and sold for joint pain